Correspondence

Disclosure Statements Regarding Hormonal Treatment of Prostate Cancer

N Engl J Med 1999; 340:1689-1690May 27, 1999

Article

To the Editor:

In compliance with the Journal's editorial rules regarding disclosure of affiliations and according to my understanding of those rules, I provided a single institutional affiliation when I submitted a letter to the editor concerning hormonal treatment of prostate cancer (March 11 issue).1 At the request of the Editors after the submission of my letter, I am providing the following information: in addition to being clinical professor of medicine (part-time) at Harvard Medical School and the Beth Israel Deaconess Medical Center, I am also chief medical officer of Praecis Pharmaceuticals, a company involved in the development of a gonadotropin-releasing hormone antagonist.

Marc B. Garnick, M.D.
Beth Israel Deaconess Medical Center, Boston, MA 02215

1 References